Group 1 - Pearl Holdings (01176) experienced a significant drop of over 33% during trading, currently down 25.64%, due to the inability of independent valuers and auditors to complete their valuation and audit work for the fiscal year 2025, affecting various financial aspects including investment properties and receivables [1] - Some gold stocks showed recovery, with Zijin Mining International (02259) up 6.89%, Lingbao Gold (03330) up 7.31%, and China Gold International (02099) up 2.59%, as the precious metals market rebounded after a sharp decline, with spot gold rising above $4,700 [1] - Paig BioPharma-B (02565) rose over 6% following the announcement of a strategic cooperation agreement with Shanghai Tengrui Pharmaceutical for the commercialization of its core product in mainland China [1] Group 2 - Crystal International (02232) saw a post-earnings decline of over 4%, currently down 2.03%, despite reporting revenues of $2.641 billion for the year ending December 31, 2025, a 6.95% increase year-on-year, and a profit attributable to shareholders of $225 million, up 12.05% [2] - Oil and gas stocks fell sharply, with Shandong Molong (00568) down 4.49% and Sinopec Oilfield Service (01033) down 4.81%, as international oil prices dropped sharply, with Brent crude down 3% to $100 [2] Group 3 - China Duty Free Group (01880) rose over 2% after announcing an agreement to acquire the entire issued share capital of DFS Cotai Limitada and related business assets from DFS Group, which is ultimately owned by LVMH [3] - Weisheng Holdings (03393) increased over 5% following a visit from the Hungarian ambassador, discussing cooperation opportunities in the energy digitalization sector [3] Group 4 - Bolecon Vision Cloud-B (02592) fell over 6%, hitting a new low since its listing, after announcing plans for clinical trials of its eye drop product for treating myopia, with the application for clinical trials submitted in December 2025 [4] - Jiaxin International Resources (03858) surged over 12%, currently up 10.65%, as tungsten concentrate prices rose significantly, reflecting a 124% increase since the beginning of the year [4] Group 5 - Aerospace Holdings (00031) dropped over 14% after issuing a profit warning, expecting a net loss of approximately HKD 270 million to 290 million for the year ending December 31, 2025, compared to a loss of HKD 83.85 million in 2024 [5] Group 6 - U.S. oil stocks saw a general increase, with Occidental Petroleum (OXY.US) up 2.06% and Chevron (CVX.US) up 1.42%, as analysts predict Brent crude prices could reach an average of $130 per barrel in Q2 and Q3 if energy infrastructure is attacked [6] - Tesla (TSLA.US) fell 3.18% following an investigation by the NHTSA into its "Full Self-Driving" system due to multiple accidents [6] Group 7 - Gold and silver stocks initially experienced a sharp decline but later rebounded, with Gold Fields (GFI.US) and AngloGold Ashanti (AU.US) seeing reduced losses after significant drops in spot gold and silver prices [7] - Alibaba (BABA.US) fell over 7% after reporting Q3 revenue of RMB 28.4843 billion, a 2% year-on-year increase, but a 67% decline in adjusted net profit [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 自願性公告 派格生物與騰瑞製藥達成派達康中國大陸獨家商業化合作 商業化目標累計銷售規模超過人民幣100億元並獲得約1.4億港幣權益金 本公告乃派格生物醫藥（杭州）股份有限公司（「本公司」）自願作出，以使本公司股 東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，近日與上海騰瑞製藥股份有限公 司（「騰瑞製藥」）就本公司核心產品派達康（「目標產品」）在中國大陸地區的商業 化合作簽署戰略合作協議。根據合作安排，雙方將整合各自在研發及商業化方面 的資源優勢，共同推進目標產品在中國大陸地區的市場推廣與商業化佈局。本次 合作標誌著公司核心產品商業化進程邁入新的階段。 根據合作協議的商業化規劃，雙方將依託騰瑞製藥覆蓋全國的商業化網絡與學術 推廣能 ...

Core Viewpoint - The approval of the innovative drug "Weipena Peptide Injection" by the National Medical Products Administration marks a significant achievement for the company and highlights the robust development of the biopharmaceutical industry in Hangzhou [1][2]. Group 1: Company Achievements - The innovative drug "Weipena Peptide Injection" (brand name: Paidakang) has been approved for market launch, showcasing the company's research capabilities [1]. - This is the fifth innovative drug approved in Hangzhou this year, reflecting the city's growing strength in biopharmaceutical innovation [1]. Group 2: Industry Development - Hangzhou accounts for 75% of the province's innovative drug applications, with 262 new drug applications registered this year, representing 40.5% of the total in the province [2]. - The city has 133 pharmaceutical manufacturing companies and approximately 103 clinical trial and new drug application institutions, indicating a solid industrial foundation [2]. - In the first three quarters, 177 clinical trial projects were approved, making up 71.9% of the total in the province [2]. Group 3: Service and Support Systems - Hangzhou has established a comprehensive and efficient service system to support biopharmaceutical innovation, focusing on regulatory and service balance [3]. - The city has implemented a "three commitments" approach to ensure timely communication and support for innovative drug companies [3]. - The market regulatory department has introduced various innovative measures to alleviate financial pressures and streamline processes for enterprises [4]. Group 4: Future Prospects - The city plans to promote a service model tailored to market regulation, benefiting more innovative entities and fostering industrial clustering [4]. - There is a commitment to enhance the entire lifecycle management and service of innovative drugs while ensuring drug safety [4].